Phase 3 study for people with Colorectal Cancer

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Pfizer
Registry number NCT07222800
Started 11 December 2025 Today 16 October 2026 Estimated completion 23 February 2030

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Sunshine Coast Haematology and Oncology Clinic Buderim QLD Recruiting
The Queen Elizabeth Hospital Woodville South SA Recruiting
Icon Cancer Centre Hobart Hobart TAS Recruiting
Monash Health Clayton VIC Recruiting
Peter MacCallum Cancer Centre Melbourne VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 800

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Histological or cytological confirmed colorectal adenocarcinoma.

* Evidence of Stage IV metastatic disease.

* No prior systemic therapy for metastatic disease.

* Eastern Cooperative Oncology Group performance status (ECOG) 0-1

* At least one measurable lesion according to RECIST 1.1 per Investigator assessment.

* Adequate hepatic, liver, and renal function

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

* Locally confirmed BRAF V600E mutation

* Locally confirmed microsatellite instability (MSI)-high or DNA mismatch repair deficiency (dMMR) colorectal cancer

* Participants with known active symptomatic CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression

* Clinically significant risk of hemorrhage or fistula

* Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study

* History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation

* Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events

* Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose

* Participants with active autoimmune diseases requiring systemic treatment within the past 2 years

* Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis

Dates on the record

Started 11 December 2025
Estimated completion 23 February 2030
Registry last updated 8 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 8 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.